# Initial characterisation of ELISA assays and the immune response of the clinically correlated SARS-CoV-2 biobank "SERO-BL-COVID-19" collected during the pandemic onset in Switzerland

Hans-Michael Kaltenbach,<sup>a,1</sup>, Fabian Rudolf, ,<sup>a,b,1,\*</sup>, Janina Linnik<sup>a</sup>, Julia Deichmann<sup>a</sup>, Therese Ruf<sup>c</sup>, Raffaele Altamura<sup>d</sup>, Edo Kapetanovic<sup>d</sup>, Derek Mason<sup>d</sup>, Bastian Wagner<sup>d</sup>, Thomas Goetz<sup>e</sup>, Lukas Mundorff<sup>e</sup>, Karin Stoll-Rudin<sup>c</sup>, Christina Krebs<sup>c</sup>, Tanja Renz<sup>e</sup>, Thomas Hochueli<sup>f</sup>, Sergio Haymoz<sup>f</sup>, Markus Hosch<sup>g</sup>, Nadine Périat<sup>g</sup>, Michèle Richert<sup>g</sup>, Sergio Sesia<sup>h,i</sup>, Daniel Paris<sup>c</sup>, Carlos Beat Quinto<sup>c,g,j,k,l</sup>, Nicole M.
Probst-Hensch<sup>c</sup>, Christoph Niederhauser<sup>n,o</sup>, Sai Reddy<sup>d</sup>, Beatrice Nickel<sup>c</sup>, Miodrag Savic<sup>g,l,m,\*</sup>

<sup>a</sup>D-BSSE ETH Zürich & Swiss Institute of Bioinformatics, Mattenstrasse 26, 4056 Basel, Switzerland <sup>b</sup>Associated Member Cantonal Crisis Staff Basel-Landschaft, 4104 Liestal <sup>c</sup>Swiss Tropical and Public Health Institute, Socinstrasse 57, 4051 Basel <sup>d</sup>D-BSSE ETH Zürich, Mattenstrasse 26, 4056 Basel <sup>e</sup>Canton Basel-Landschaft Medical Association, 4104 Liestal <sup>f</sup>Office for Military Affairs and Civil Protection Canton Basel-Landschaft, 4104 Liestal <sup>g</sup>Department of Health, Economics and Health Directorate Canton Basel-Landschaft, 4104 Liestal <sup>h</sup>University of Berne, 3000 Berne <sup>i</sup>University Hospital of Berne, 3000 Berne <sup>j</sup>Department of Public Health, Health Professions and Medicines, 4000 Basel <sup>k</sup>Swiss Medical Association <sup>l</sup>University of Basel, 4000 Basel <sup>m</sup>University Hospital of Basel, 4000 Basel

<sup>n</sup>Interregional Blood Transfusion SRC, 3000 Bern <sup>o</sup>Institute for Infectious Diseases, University of Bern, 3000 Bern

# Abstract

Background To accurately measure seroprevalance in the population, both

July 3, 2020

 $<sup>^{*} \</sup>rm correspondence$  should be addressed to fabian.rudolf@bsse.ethz.ch or miodrag.savic@usb.ch

<sup>&</sup>lt;sup>1</sup>these authors contributed equally

> the expected immune response as well as the assay performances have to be well characterised. Here, we describe the collection and initial characterisation of a blood and saliva biobank obtained after the initial peak of the SARS-CoV-2 pandemic in Switzerland.

> Methods Two laboratory ELISA assays measuring IgA & IgG (Euroimmun), and IgM & IgG (Epitope Diagnostics) were used to characterise the biobank collected from 349 re- and convalescent patients from the canton of Basel-Landschaft.

> **Findings** The antibody response in terms of recognized epitopes is diverse, especially in oligosymptomatic patients, while the average strength of the antibody response of the population does correlate with the severity of the disease at each time point.

Interpretation The diverse immune response presents a challenge when conducting epidemiological studies as the used assays only detect  $\sim 90\%$  of the oligosymptomatic cases. This problem cannot be rectified by using more sensitive assays or lower cut-offs as they concomitantly reduce specificity.

**Funding** Funding was obtained from the "Amt für Gesundheit" of the canton Basel-Landschaft, Switzerland.

*Keywords:* COVID-19, Serology, Biobank, Immune response, oligosymptomatic patients

#### 1 1. Introduction

Effective host responses to viral infections, including those to coronaviruses, are driven by adaptive immunity [1]. For endemic or previously emerging coronaviruses, the antibody response has been correlated with protection from re-infection for a varying period of time. In SARS-CoV-2 infections, most studies on antibody kinetics are based on severe or hospitalized

patients, even though subclinical or even oligosymptomatic patients represent the majority of cases. Less severe cases of SARS-CoV-2 (as well as other
endemic CoVs) are associated with lower antibody responses, and therefore
pose a challenge for accurate detection using serological assays.

However, one of the most important correlates of immunological pro-11 tection is the presence of neutralizing antibodies, which is preferably mea-12 sured by using functional assays with replication competent virus [2]. For 13 COVID-19 patients, such assays are time consuming and must be conducted 14 in Biosafety Level 3 facilities, which renders them infeasible for wide-scale 15 testing. Some alternative functional assays are based on pseudotyped or 16 chimeric viral particles [3], but these reagents are neither trivial to produce 17 nor do they scale to large sample sizes. The most feasible alternative assays 18 are therefore binding assays, such as enzyme-linked immunosorbent assays 19 (ELISA), and preferably report on the quantity of antibodies binding to neu-20 tralizing epitopes such as the receptor binding domain (RBD) of the spike 21 protein [4]. 22

Current clinically approved ELISA tests either bind to the nucelocapsid 23 (NCP) protein or (part of) the spike protein (which includes the RBD). Both 24 of these proteins, but especially the NCP, are known to generate a strong 25 host immune response in other beta-coronaviruses [5, 6]. In contrast, nearly 26 all neutralising antibodies against SARS-CoV-2 discovered to date bind to 27 the small RBD portion of the spike protein [7, 8], and currently available 28 commercial assays indeed insufficiently predict neutralisation [2]. The pres-29 ence and characterization of antibody responses in COVID-19 patients by 30 serological assays has been described in several reports [9, 10, 11, 12, 13, 14]; 31 a key observation is that across many patients, antibodies are detected at 32  $\sim 10$  days post-onset of symptoms. 33

The performance of assays is characterized by their sensitivity and specificity [15]. To-date, most commercial ELISA performance validations were obtained from biobanks relying on hospitalised patients; this positive patient cohort will likely have higher antibody levels than milder, non-hospitalized patients [16]. This is also observed for SARS-CoV-2 infections [17]. It is thus unclear if the available tests are sufficiently sensitive to also detect oligosymptomatic cases.

Here, we describe the collection and initial analysis of a blood biobank 41 representative for the observed COVID-19 symptomatic range in the pop-42 ulation of Switzerland. The positive cohort in this biobank consists of 341 43 samples obtained from participants determined to have SARS-CoV-2 (PCR-44 positive test) in various symptomatic and post-symptomatic stages. The 45 negative cohorts include 115 samples obtained from PCR-negative tested 46 participants, and 150 samples of blood donors from the 2016/17 flu sea-47 son. The distribution in age and disease severity in this biobank is similar 48 to that reported for other areas in Western Europe. For each sample, we 49 measured the antibody response toward the NCP and S1 proteins using the 50 ELISA tests for IgM and IgG from Epitope Diagnostics and IgA and IgG 51 from Euroimmun, and characterized the performance of these assays. The 52 specificity of both the Euroimmun IgG and the Epitope Diagnostics IgM 53 assays was close to 100%, while the other two tests showed specificities of  $\sim$ 54 96% and lower. The sensitivity of the IgA and IgG tests was only sufficient 55 to detect ~ 90% of the cases, while the IgM test only detected ~ 50%. Pre-56 vious studies reported a low and late IgM response, especially in less severe 57 COVID-19 patients [10, 11], which might partially explain the low IgM test 58 sensitivity. Taken together, our data indicates that the immune response in 59 oligosymptomatic patients is diverse and ill captured with the two employed 60

61 serological assays.

# 62 2. Materials & methods

# 63 2.1. Ethics statement

This study is part of the project 'COVID-19 in Baselland Investigation and Validation of Serological Diagnostic Assays and Epidemiological Study of Sars-CoV-2 specific Antibody Responses (SERO-BL-COVID-19)' approved by the ethics board "Ethikkommission Nordwest- und Zentralschweiz (EKNZ)", Hebelstrasse 53, 4056 Basel representative of Swissethics under the number (2020-00816).

Every participant has received a written informed consent at least 24 hours before participating in this study (attached original document in German language). The participants had to sign the written informed consent and needed to show it in order to be given access to the test facility. The participants could withdraw their participation at any time without stating any reason.

# 76 2.2. Collection of samples

# 77 2.2.1. Blood Collection

Venous blood was taken by puncturing a disinfected cubital or similar area using a BD safety-lock system into a vacutainer. In total, 10–12 mL each for EDTA-blood serum was taken. The blood collection was performed by a medical assistant or nurse. After blood collection, the samples were either transferred to the diagnostic lab or directly processed on site in the make-shift laboratory.

# 84 2.2.2. Saliva Collection

Saliva was collected non-invasively using the dedicated Salivette tubes (Sarstedt Cat. # 51.1534). In short, the participant delivered saliva into an adsorbent filter, which was then placed by the participant in the Salivette tube. After handover to the medical staff, the saliva was centrifuged on site at 4°C using 1,000× g for 2 min to remove cells and debris. The tube was then rapidly frozen using a salted ice-water bath and stored at  $-20^{\circ}$ C before transporting to the lab on dry ice and storage at  $-80^{\circ}$ C until further use.

# 92 2.2.3. Plasma and PBMC isolation and cell cryopreservation

Density gradient separation was used in peripheral blood mononuclear 93 cell (PBMC) isolation. 12 mL of fresh donor blood was received in  $3 \times 4$  mL 94 plastic whole blood tubes with spray-coated K<sub>2</sub>EDTA BD Vacutrainer<sup>TM</sup> 95 (Becton Dickinson, Cat. # 367844). The whole blood was diluted in 1:1 ratio 96 with 12 mL of PBS (w/o Ca<sup>2+</sup> and Mg<sup>2+</sup>). The total volume of diluted blood 97 (24 mL) was gently and slowly layered on 14 mL of Ficoll Lymphoprep<sup>TM</sup> 98 (STEMCELL, Cat. # 07861). Samples were centrifuged at 400× g 40 min, 99 22°C, no brakes. 14 mL of plasma was transferred in a 15 mL conical tube 100 and stored at 4°C. The layer of mononuclear cells was aspirated and trans-101 ferred in a 50 mL conical tube containing 25 mL of PBS (w/o  $\rm Ca^{2+}$  and 102  $Mg^{2+}$ ). Cells were washed  $300 \times g 8 \min$ ,  $22^{\circ}C$ , with brakes. Washing was 103 repeated with an additional 25 mL of PBS ( $w/o \ Ca^{2+}$  and  $Mg^{2+}$ ). Mononu-104 clear cells were subsequently resuspended in 1 mL of freezing media (heat 105 inactivated FBS supplemented with 10% DMSO) and aliquoted into two 1.5 106 mL cryogenic tubes (Nalgene System, Thermo Scientific, Cat. # 5000-1020). 107 The cryogenic tubes were put into freezing containers Mr.Frosty<sup>TM</sup> (Thermo 108 Scientific, Cat. # 5100-0001) and the containers were immediately placed 109

into an -80°C freezer for 24 hrs, and then transferred into a liquid nitrogen
tank.

#### 112 2.2.4. Point of care validation

To perform the point of care test (POCT) validation, a capillary blood sample was taken from each subject by puncturing the end of a finger and taking the blood with a micro pipette. Immediately after collecting, the blood was put in the lateral flow chamber of the POCT and after 15 minutes the result was visually scored as positive or negative by the medical assistant. Additionally, the tests were imaged using a Nikon D5000 camera.

## 119 2.2.5. Blood donor cohort

Samples from nonremunerated blood donors originate from the Swiss cantons of Thurgau, Basel, Bern, Waadt and Geneva, and were taken during the pre-pandemic period 16th and 17th December 2016. These samples were frozen as EDTA plasmas on microtiterplates for  $-20^{\circ}$ C.

# 124 2.3. ELISA analysis

The following four commercially available immunoassays were characterized in the study: the Anti-SARS-CoV-2-ELISA-IgA (Euroimmun AG, Lübeck, # EI 2606-9601 A), the Anti-SARS-CoV-2-ELISA-IgAG (Euroimmun AG, Lübeck, # EI 2606-9601 G), the EDI Novel Coronavirus COVID-19 IgM ELISA kit (Epitope Diagnostics, Inc., # KT-1033) and the EDI Novel Coronavirus COVID-19 IgG ELISA kit (Epitope Diagnostics, Inc., #KT-1032). All ELISA kits were CE and IVD labeled.

To enable a quantitative comparison between ELISA experiments, we calculated fold changes in OD relative to the assay- and run-specific cut-off

values  $(OD_{sample}/OD_{cut-off})$ , where  $OD_{cut-off} = 1.1 \times OD_{cal}$  for both Euroim-134 mun ELISAs,  $OD_{cut-off} = (1.1 + 0.18) \times OD_{NC}$  for EDI IgG and  $OD_{cut-off} =$ 135  $(1.1 + 0.10) \times OD_{NC}$  for EDI IgM, where  $OD_{cal}$  and  $OD_{NC}$  are calibration 136 respectively average negative control values as described by the manufac-137 turers. Note that fold changes are not comparable between Euroimmun and 138 EDI ELISA test kits because the assays show large differences in dynamic 139 range and saturation. Detailed calculation can be found in the supplemen-140 tary methods. 141

#### 142 2.4. Statistical analysis

Patient data and results of POCTs were originally stored in the RED-143 Cap database system of the Canton Hospital Basel-Landschaft. Results 144 from ELISA tests were entered into Excel worksheets. All data were pre-145 processed and a common database created using in-house scripts in R [18]. 146 Statistical analysis and creation of figures and tables was carried out using R; 147 binomial confidence intervals are 95%-Clopper-Pearson intervals calculated 148 using exactci() from package PropCIs [19]. A refresher for the calculation 149 of specificity and sensitivity calculation can be found in the supplementary 150 methods. 151

#### 152 2.5. Role of the funding source

The sponsor had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.

# 156 3. Results

#### 157 3.1. Study design & cohorts

The goal of our study design was to collect a representative cohort of 158 COVID-19 disease manifestation during the first wave of COVID-19 in the 159 canton Basel-Landschaft, Switzerland. During the initial phase of the pan-160 demic, only people in risk groups showing symptoms were tested; later, 161 testing was extended to all people showing symptoms and 5311 people had 162 been tested in the canton at the beginning of study recruitment, with 802 163 (15.1%) positive and 4509 (84.9%) negative PCR test results. The cases 164 were mostly observed close to or in areas with a high frequency of commut-165 ing to the city of Basel, but the ratio of positive tests showed no apparent 166 bias for or against rural communities. 167

All RT-PCR-tested individuals were eligible for participation except when 168 they were <18 years of age, had a severely compromised immune system, 169 were hospitalized at the time of sample collection, or were deceased. From 170 these, 349 positive individuals committed to participating in the study, 171 and 111 negative individuals were randomly selected. We aimed for suffi-172 cient sample size for two positive cohorts: an 'acute' cohort with diagnosed 173 COVID-19 up to 12 days before study entry, and a 'convalescent' cohort 174 with more than 12 days between positive diagnosis and study entry. 175

Individuals were continuously recruited during a 2 week window from 11. April 2020 to 22. April 2020 and visited the 'Abklärungsstation COVID-19' in Münchenstein, Switzerland. The medical history and the status were recorded in a doctors interview, the vital parameters were acquired, and saliva and blood samples were collected. All participants of the positive cohort were guided through the building, while the negative cohort was

- examined in a make-shift field hospital erected next to the building to mini-
- <sup>183</sup> mize the danger of infection with COVID-19. Participant characteristics are
- <sup>184</sup> summarized in Table 1.

Cohort	PCR pos, $\leq 7d$	PCR pos, $> 7d \& \le 12d$	PCR pos, $> 12d$	PCR neg, $> 5d$
	(N = 31)	(N = 46)	(N = 272)	(N = 111)
Sex				
female	17 (55%)	25 (54%)	130 (48%)	63~(57%)
male	14~(45%)	21 (46%)	142~(52%)	48 (43%)
Age				
years, median (range)	45 (21-80)	51 (20-80)	51.5(17-93)	48 (19-87)
Weight				
kg, median (range)	73 (51-110)	72 (40-109)	76 (49-135)	73 (47-130)
Height				
cm, median (range)	173.5 (157-187)	172 (150-191)	173 (72-198)	172(149-195)
SpO2				
%, median (range)	98 (93-99)	98 (88-99)	98 (85-99)	98 (95-99)
Total days ill				
0-5 days	6 (19%)	1 (2%)	28 (10%)	
510  days	15 (48%)	23 (50%)	146~(54%)	
$10{-}14$ days	10 (32%)	22 (48%)	98~(36%)	_

Table 1: Characteristics of patients included in the study.

Distribution of ages and gender for the positive cohort are similar to the 185 age and gender structure of the canton, except for the age between 40-65186 which are over-represented and >80 which are under-represented (Table 2 187 and Supplementary Figure 1). From the 349 positive participants, 35 (10%)188 were bedridden during the acute disease, 62 (18%) required help for their 189 daily activities, while 244 (72%) had no restrictions. Similar distributions 190 are reported elsewhere. All age groups were affected equally, however severe 191 cases were more pronounced in the older population. Increasing disease 192 severity correlated with the experienced symptoms; bedridden cases suffered 193 approximately 10 or more days, cases requiring help  $\sim 10$  days, and the 194 oligosymptomatic cases between 5 to 15 days. 195

	Age groups						
	$15 - 19^*$	20-29	30-39	40-49	50-64	65 - 79	80+
Overall	5 (1.1%)	55 (12%)	64 (13.9%)	99 (21.5%)	159 (34.6%)	68 (14.8%)	10 (2.2%)
Severity of illne	ss						
Not ill	1 (20%)	13~(24%)	23~(36%)	24 (24%)	29 (18%)	18 (26%)	3(30%)
No restrictions	4 (80%)	36 (65%)	34 (53%)	53 (54%)	91 (57%)	28 (41%)	4 (40%)
Help needed	0 (0%)	6 (11%)	6 (9%)	18 (18%)	22 (14%)	9 (13%)	1 (10%)
Bedridden	0 (0%)	0 (0%)	1(2%)	4 (4%)	17 (11%)	13~(19%)	2(20%)
Total days ill							
0-5 days	0 (0%)	7 (17%)	5(12%)	7 (9%)	11 (8%)	5 (10%)	0 (0%)
$5{-}10 \text{ days}$	3~(75%)	19 (45%)	24 (59%)	39~(52%)	72 (55%)	24 (48%)	3~(43%)
$10{-}15 \text{ days}$	1 (25%)	16 (38%)	12 (29%)	29~(39%)	47 (36%)	21 (42%)	4 (57%)
Baselland (2019)	13924~(5.6%)	30882 (12.4%)	35666 (14.3%)	39190 (15.7%)	65017 (26.1%)	45175 (18.1%)	19054 (7.7%

Table 2: Age structure of study cohort stratified by severity and by duration of symptoms. Last row shows distribution of ages 15+ in canton of Basel-Land in 2019 for reference. \*Note that our study cohort does not include minors with less than 18 years of age.

We use two negative cohorts; (i) samples from  $150 \ 2016/17$  influenza 196 period blood donors, and (ii) our negative cohort. These cohorts should 197 strengthen the specificity calculations, but also help to address cross-reactivity 198 to viruses currently in circulation. However, the PCR test is prone to false 199 negatives, and we therefore expect to find a small number of incorrectly 200 diagnosed individuals. In line with the reported false negative rate of 15– 201 25% [20, 21], we identified four individuals with negative PCR results but 202 seroconverted in both Euroimmun IgG and IgA and Epitope Diagnostics 203 (EDI) IgG. We consider these four individuals as false negative PCR re-204 sults and removed them from the dataset. All results are only influenced 205 marginally by this step. 206

# 207 3.2. Performance characteristics of ELISA tests

#### 208 3.2.1. Sensitivity & specificity

We performed the EDI and Euroimmun assays according to the manufac-209 turers instructions on all samples. The obtained data were normalized (see 210 Material and Methods section) to make results comparable between experi-211 ments. The reported fold-changes are defined as the ratio between measured 212 OD and the classification cut-off OD specified by the manufacturer (Figure 1 213 & Supplementary Figure 2). Positive/negative classification was performed 214 according to manufacturer's instructions, and the assay performance was 215 calculated therefrom. 216

We used a patient's assignment to the PCR-positive or PCR-negative cohort together with the corresponding ELISA test result for calculating performance characteristics for all four assays. The values considering all data are shown in the top of Table 3. We find specificities of the IgG-based assays of about 98%-99%, while IgA shows considerably lower and IgM con-




Figure 1: **Overview on ELISA results.** Epitope Diagnostics (EDI) and Euroimmun assays were performed with serum from 607 individuals. The negative cohort consists of 150 serum samples collected during the 2016/17 influenza period and 110 serum samples from PCR-negative individuals from 2020. Positive cases are stratified by days post symptoms onset (left) and additionally stratified by disease severity (right). Fold changes are defined as the ratio between measured OD and the classification cut-off OD specified by the manufacturer. Grey area indicates the range where serum samples are classified as uncertain; samples above (below) this area are classified as positive (negative).

- <sup>222</sup> siderably higher specificity overall. To determine potential cross-reactivity
- 223 of the assays, we separately calculated the specificity from the 150 sam-
- ples of the 2016 blood donor cohort (Table 3 (bottom)). Nevertheless, the
- <sup>225</sup> histogram of all assays and data show overlap between the cohorts (Supple-
- <sup>226</sup> mentary Figure 3).

	EDI				Euroimmun			
	Serum		Plasma		Serum			
	IgM	IgG	IgM	IgG	IgA	IgG	IgG 1.5×	
TP	161	287	176	280	304	291	272	
FP	3	6	11	12	22	2	0	
$_{\rm TN}$	257 (2)	254 (7)	100 (11)	99 (13)	238 (12)	258 (2)	260(0)	
FN	184 (35)	58 (16)	161 (36)	57 (14)	41 (15)	54 (12)	73 (0)	
Se [CI], $\%$	$46.7\ [41.3,\ 52.1]$	$83.2 \ [78.8,  87]$	$52.2 \ [46.7, \ 57.7]$	$83.1\ [78.6,\ 86.9]$	$88.1\ [84.2,\ 91.3]$	$84.3 \ [80.1, \ 88]$	$78.8 \ [74.1, \ 83]$	
Sp [CI], $\%$	$98.8 \ [96.7, \ 99.8]$	$97.7 \ [95, \ 99.1]$	$90.1 \ [83,  94.9]$	$89.2 \ [81.9, \ 94.3]$	$91.5 \ [87.5, \ 94.6]$	$99.2 \ [97.2, \ 99.9]$	$100 \ [98.6, \ 100]$	
2016 blood donors								
TN	150 (0)	147 (3)	_	_	136 (7)	150 (2)	150 (0)	
FP	0	3	_	_	14	0	0	
Sp [CI], $\%$	100 [97.6, 100]	98 [94.3, 99.6]	_	_	90.7 [84.8, 94.8]	100 [97.6, 100]	100 [97.6, 100]	

Table 3: Top: Number true positive (TP), false positive (FP), true negative (TN), false negative (FN), sensitivity (Se) and specificity (Sp) for Epitope Diagnostics (EDI) serum and plasma samples and Euroimmun ELISA serum samples for all cohorts. All samples with uncertain result were considered negative for the analysis (number of uncertain samples shown in brackets). Column IgG  $1.5 \times$  for Euroimmun corresponds to using a threshold of 1.5 instead of 1.1 for the OD-ratio. Bottom: specificity based on serum samples of negative 2016 blood donor cohort only.

The IgG- and IgA-based assays show overall sensitivities above 87%, 227 while the sensitivity of IgM is extremely low at slightly above 50%. How-228 ever, the different types of antibodies act at different stages of the immune 229 response. We therefore stratified the calculation of assay sensitivities by 230 days after onset of symptoms into three categories: 14 days or less, 15 to 20 231 days, and 21 days or more (Table 4 & Supplementary Figure 4). Sensitivities 232 increase with days after onset of symptoms for both IgG assays from about 233 50% to 95%. The sensitivity of the IgM assay remains low for all strata, 234 while IgA already shows substantially higher sensitivities than all other as-235 says for less than 14 days after onset of symptoms. Specifically, sensitivity 236 is low for the EDI Diagnostics IgM assay, reaching a maximum of 64% for 237 two to three weeks after onset of symptoms. Both IgG assays show over-238 all sensitivities below 90%, but sensitivities increase to 95% or higher three 239 weeks after onset of symptoms. The Euroimmun IgA sensitivity is highest 240 among the four assays for less than two weeks after onset of symptoms with 241 82% and also reaches about 95% after three weeks or more after onset of 242 symptoms. 243

EDI ELISA							
		$\operatorname{IgM}$			IgG		
	$\leq 14~{\rm days}$	15–20 days	$\geq 21~{\rm days}$	$\leq 14~{\rm days}$	15–20 days	$\geq 21~{\rm days}$	
TP	20	32	109	29	44	214	
FN	34(5)	20 (4)	130(26)	25(2)	8 (1)	25(13)	
Se [CI], $\%$	$37\ [24.3,\ 51.3]$	$61.5 \ [47, \ 74.7]$	$45.6\ [39.2,\ 52.2]$	$53.7 \ [39.6, \ 67.4]$	$84.6\ [71.9,\ 93.1]$	$89.5 \ [84.9, \ 93.1]$	
			Euroimmun El	LISA			
	IgA			IgG			
	$\leq 14~{\rm days}$	15-20  days	$\geq 21~{\rm days}$	$\leq 14~{\rm days}$	15–20 days	$\geq 21~{\rm days}$	
TP	40	46	218	23	42	226	
FN	14(5)	6 (1)	21 (9)	31 (3)	10 (4)	13 (5)	
Se [CI], $\%$	$74.1 \ [60.3, \ 85]$	$88.5 \ [76.6, \ 95.6]$	$91.2 \ [86.9, \ 94.5]$	$42.6\ [29.2,\ 56.8]$	$80.8\ [67.5,\ 90.4]$	$94.6\ [90.9,\ 97.1]$	

Table 4: Sensitivity of EDI (top) and Euroimmun (bottom) ELISA stratified by days after onset of symptoms. All samples with uncertain result were considered negative for the analysis (number of uncertain samples shown in brackets).

We performed the same analysis stratified by three levels of disease 244 severity-'no restriction', 'help needed', and 'bedridden'-and combined 245 these levels with two levels for days after onset of symptoms: short ( $\leq 21$ 246 days) or long (> 21 days). The resulting sensitivities and specificities and 247 their 95% confidence intervals are given in Table 5. As expected, sensitivities 248 also increase with severity of symptoms for both less and more than three 249 weeks after onset of symptoms, but sample sizes are comparatively small for 250 shorter time and higher severity. Notably, the IgG response is detectable in 251 all samples of the 'bedridden' cohort > 21 days, and is then comparable to 252 the manufacturers characterisation on this subset. 253

			EDI	IgM			
	Bedr	idden	Help	Help needed		No restrictions	
	$\leq 21 \mathrm{d}$	> 21d	$\leq 21 \mathrm{d}$	> 21d	$\leq 21 \mathrm{d}$	> 21d	
TP	7	20	15	23	36	60	
FN	2 (2)	6 (3)	4 (0)	20 (6)	54 (8)	98 (16)	
Se [CI], $\%$	$77.8\ [40,\ 97.2]$	$76.9\ [56.4,\ 91]$	$78.9\ [54.4,\ 93.9]$	$53.5 \ [37.7, \ 68.8]$	$40\ [29.8,\ 50.9]$	$38 \ [30.4, \ 46]$	
	EDI IgG						
	Bedr	idden	Help 1	Ielp needed No restriction		rictions	
	$\leq 21 \mathrm{d}$	> 21d	$\leq 21 \mathrm{d}$	> 21d	$\leq 21 \mathrm{d}$	> 21d	
TP	8	25	17	39	58	140	
FN	1(0)	1 (1)	2 (0)	4 (2)	32 (4)	18 (9)	
Se [CI], $\%$	$88.9\ [51.8,\ 99.7]$	$96.2 \ [80.4, \ 99.9]$	$89.5 \ [66.9, \ 98.7]$	$90.7\ [77.9,\ 97.4]$	$64.4 \ [53.7,  74.3]$	$88.6 \ [82.6, \ 93.1]$	
	Euroimmun IgA						
	Bedridden		Help needed		No restrictions		
	$\leq 21 \mathrm{d}$	> 21d	$\leq 21 \mathrm{d}$	$\leq 21d$ > 21d		> 21d	
TP	9	25	18	40	71	141	
FN	0 (0)	1(0)	1(0)	3 (2)	19 (6)	17 (7)	
Se [CI], $\%$	$100\ [66.4,\ 100]$	$96.2 \ [80.4, \ 99.9]$	$94.7\ [74,\ 99.9]$	$93\ [80.9,\ 98.5]$	$78.9\ [69,\ 86.8]$	89.2 [83.3, 93.6]	
			Euroim	nun IgG			
	Bedridden		Help needed		No restrictions		
	$\leq 21 \mathrm{d}$	> 21d	$\leq 21 \mathrm{d}$	> 21d	$\leq 21 \mathrm{d}$	> 21d	
TP	7	25	16	42	53	148	
$_{\rm FN}$	2(0)	1 (1)	3(0)	1(0)	37 (7)	10 (4)	
Se [CI], $\%$	$77.8 \ [40, \ 97.2]$	$96.2 \ [80.4, \ 99.9]$	$84.2\ [60.4,\ 96.6]$	$97.7\ [87.7,\ 99.9]$	$58.9 \ [48,  69.2]$	$93.7 \ [88.7,  96.9]$	

Table 5: Sensitivities stratified by severity of illness. All samples with uncertain result were considered negative for the analysis (number of uncertain samples shown in brackets).

# 254 3.2.2. Reproducibility and linearity

Intra-assay variability was determined by calculating the mean, stan-255 dard deviation, and coefficient of variation of the measured OD ratios based 256 in 5 replicate measurements of 8 samples with values ranging from at or 257 below the threshold limit to about the 75% quartile in the two IgG and 258 IgA assays (Supplementary Table 5 & Supplementary Figure 6). In general, 259 reproducibility was high with coefficients of variation of 5% or smaller in 260 samples well above the threshold. This variation increased to  $\sim$  10% at 261 or below the threshold. It is trivial but important to state that, at the 262 threshold, this variability can lead to different classification in each repe-263 tition. Last, different samples show different variabilities in the two IgG 264 assays, possibly indicating the difference between the binding epitope and 265 assay manufacturing. 266

We investigated the assay linearity using two-fold serially diluted serum 267 samples from 5 individuals with high OD values for IgG (Supplementary 268 Figure 11). Both Euroimmun assays showed a good linearity over a dilution 269 range of 64-fold  $(2^6 \text{ dilutions})$ , while the IgG Epitope Diagnostics (EDI) 270 assay is linear only in a 16-fold  $(2^4)$  dilution range. Additionally, both 271 IgG assays show good agreement along the dilutions (Supplementary Figure 272 10), suggesting that—after normalization and scaling—the IgG assays give 273 comparable quantitative results. No data of sufficient quality was acquired 274 for a discussion of the IgM assay (Supplementary Figure 11). Additionally, 275 we found that the IgG, but not the IgM, assay from EDI is sensitive to 276 haemolysis (Supplementary Figure 12). 277

## 278 3.3. Kinetics of seroconversion

Our positive cohort can give insight into the kinetics of seroconversion at the population level for different antibody types and epitopes and a broad range of disease manifestations. The two ELISA tests employ different epitopes: the EDI test recognizes the SARS-CoV-2 nucleocapsidprotein and uses IgG and IgA while the Euroimmun test recognizes the S1 portion of the spike protein using IgG and IgM.

For all antibody types, the strength of the response over time correlated 285 with severity of the symptoms (Figure 2A). We only measured a well dis-286 cernible IgM response in the "bedridden" group and a slight response in 287 the "help needed" group, while it was largely absent from the "no restric-288 tion" group. On the other hand, the IgA and IgG response is measurable 289 in most samples. The average response is higher when "bedridden", while 290 similar antibody response levels are observed for "no restriction" and "help 291 needed". 292

In most viral host responses, the earliest measurable response is IgM 293 followed by IgG and IgA. Surprisingly, but in line with other reports for 294 SARS-CoV-2 [10, 11] as well as observations for SARS and MERS, all three 295 antibody types reacted within a similar timeframe. The earliest detection, 296 within a week of symptom onset, was for IgA, followed by IgM and IgG both 297 detected from week 2. IgM then peaked 2–3 weeks and IgA 3–4 weeks post 298 symptom onset, while no decline for IgG was measured. The temporal order 299 of these peaks can be expected based on the half-life time of the different 300 antibody types in the blood. 301

These observations are further substantiated from observing the responses on the level of the individuals. Most interestingly, we find a robust IgG response against the NCP early on, whereas the response to the spike protein




Figure 2: A: Log<sub>2</sub>-fold changes in ELISA signal for each assay by time after symptoms onset and by disease severity. Data was fitted using smoothing splines to visualize trends (figure shows fits and 95% confidence intervals). Grey area indicates the range where serum samples are classified as uncertain; samples above (below) this area are classified as positive (negative). B: Scatterplots comparing log<sub>2</sub>-fold changes in IgA vs IgG measured by Euroimmun ELISA (left), IgG measured by Euroimmun ELISA vs IgG measured by Epitope Diagnostics (EDI) ELISA (center), and Euroimmun IgA vs EDI IgG (right) by disease severity. C: As in B but with days after onset of symptoms. Fold-changes are defined as the ratio between measured OD and the classification cut-off OD specified by the manufacturer.

seems to be more prevalent at later time points (Figure 2A). However, neither IgG response is significantly different depending on the severity of the disease. The IgA response against the spike protein is produced rapidly in the absence of an IgG response but subsides at later time points when the IgG response becomes dominant.

#### 310 4. Discussion

Here, we describe the collection and initial characterisation of a blood 311 bank from the affected population of the canton Basel-Landschaft, Switzer-312 land. Almost 50% of the people fallen ill with COVID-19 participated in 313 this study and the biobank is therefore exemplary for an outbreak in a 314 western European community. In particular, the COVID-19 severity and 315 symptoms in the biobank samples closely follow the reported distributions 316 elsewhere. We might have slightly biased our cohorts toward less severe 317 cases, by excluding samples from actively hospitalized or deceased patients. 318 Since only 11 cases remained in the hospital at the time of recruitment, this 319 bias is likely small. Overall, we consider the largely representative sample a 320 strength of our biobank, as it allows us to estimate the kinetics of serocon-321 version and assay performance characteristics on samples closely resembling 322 those expected in population-wide studies for sero-prevalence. 323

We find that both specificity and sensitivity are below the manufacturers specifications for all four tests, and observe similar sensitivities only for our 'bedridden' group. This indicates that characterizations by the manufacturers are likely based on 'severe' cohorts, which limits their applicability and impairs planning of sero-prevalence studies. We also find that the IgA and IgG assays allow for quantification within a relatively narrow range: the

linear range of the Euroimmun assay covers approximately a 64-fold dilu-330 tion range and the EDI assay a 16-fold dilution range. When calculating 331 sensitivities and specificities with our cohort, the IgA test shows the highest 332 sensitivity, followed by the two IgG assays. The poor sensitivity of the IgM 333 test is either due to the absence of a dedicated IgM response [22] in line 334 with previous reports or poor test performance. The highest specificity is 335 achieved with the Euroimmun IgG test. The specificity could be further 336 boosted by a higher cut-off as previously reported, however accompanied by 337 a concurrent drop in sensitivity (Supplementary Tables 14, 15, 16). 338

The average strength of the antibody response, as measured by the ra-339 tios, correlates with the severity of the disease at each time point. However, 340 the differences vanish the longer post-symptoms onset the individuals are, 341 and the measured amount in an individual is not predictive for the sever-342 ity of the disease. Surprisingly, but similar to earlier reports, we measured 343 that the temporal order of the response is shifted. IgA is measured within 344 1–2 weeks after symptoms onset, followed by the IgG response at week 2–3, 345 while a clear IgM response is absent. Especially at earlier time points, the 346 IgA response is stronger than the IgG response as measured using the S1 347 spike protein epitope in the Euroimmun assay. To fully understand what 348 the obtained values reflect and how they correlate with diseases and pro-349 tection from disease, further analyses are planned including measuring the 350 strength to neutralize pseudo-typed viral particles and analysing the indi-351 vidual antibodies by sequencing the PBMCs. However, our current data 352 help to understand the limitations of the current antibody tests on the mar-353 ket and serve as the basis to interpret ongoing studies on other lab assay 354 characterization, POCT performances and PBMC sequencing. 355

# 356 Acknowledgement

This study was sponsored by Jürg Sommer, head of the "Amt für Gesundheit", and the logistics of the sample collection were provided by the crisis staff and the civil protection service of the canton Basel-Landschaft. FR is funded by the NCCR 'Molecular Systems Engineering'. Funding for JD from the two Cantons of Basel through project grant PMB-01-17 granted by the ETH Zurich is acknowledged.

<sup>363</sup> Funding for TR, DP, BN Funding for MS

# 364 **References**

- [1] A. T. Huang, B. Garcia-Carreras, M. D. Hitchings, B. Yang, L. Katzelnick, S. M. Rattigan, B. Borgert, C. Moreno, B. D. Solomon,
  I. Rodriguez-Barraquer, et al., A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease,
  medRxiv (2020).
- [2] J. AJ, A. MJ, et al., Performance of six SARS-CoV-2 immunoassays in
  comparison with microneutralisation, Journal of clinical virology: the
  official publication of the Pan American Society for Clinical Virology
  129 (2020) 104512.
- [3] F. Schmidt, Y. Weisblum, F. Muecksch, H.-H. Hoffmann, E. Michailidis,
  J. C. Lorenzi, P. Mendoza, M. Rutkowska, E. Bednarski, C. Gaebler,
  et al., Measuring SARS-CoV-2 neutralizing antibody activity using
  pseudotyped and chimeric viruses, bioRxiv (2020).

- <sup>379</sup> [4] F. Amanat, D. Stadlbauer, S. Strohmeier, T. H. Nguyen,
  <sup>380</sup> V. Chromikova, M. McMahon, K. Jiang, G. A. Arunkumar, D. Jur<sup>381</sup> czyszak, J. Polanco, et al., A serological assay to detect SARS-CoV-2
  <sup>382</sup> seroconversion in humans, Nature medicine (2020) 1–4.
- [5] Y. Shi, Y. Yi, P. Li, T. Kuang, L. Li, M. Dong, Q. Ma, C. Cao, Diagnosis
  of severe acute respiratory syndrome (SARS) by detection of SARS
  coronavirus nucleocapsid antibodies in an antigen-capturing enzymelinked immunosorbent assay, Journal of clinical microbiology 41 (2003)
  5781–5782.
- [6] P. D. Burbelo, F. X. Riedo, C. Morishima, S. Rawlings, D. Smith,
  S. Das, J. R. Strich, D. S. Chertow, R. T. Davey Jr, J. I. Cohen,
  Sensitivity in detection of antibodies to nucleocapsid and spike proteins
  of severe acute respiratory syndrome coronavirus 2 in patients with
  coronavirus disease 2019, The Journal of infectious diseases (2020).
- [7] F. Wu, A. Wang, M. Liu, Q. Wang, J. Chen, S. Xia, Y. Ling, Y. Zhang,
  J. Xun, L. Lu, et al., Neutralizing antibody responses to SARS-CoV-2
  in a COVID-19 recovered patient cohort and their implications (2020).
- [8] T. F. Rogers, F. Zhao, D. Huang, N. Beutler, A. Burns, W.-t. He,
  O. Limbo, C. Smith, G. Song, J. Woehl, et al., Isolation of potent
  SARS-CoV-2 neutralizing antibodies and protection from disease in a
  small animal model, Science (2020).
- [9] N. M. Okba, M. A. Müller, W. Li, C. Wang, C. H. GeurtsvanKessel,
  V. M. Corman, M. M. Lamers, R. S. Sikkema, E. de Bruin, F. D. Chandler, et al., Severe acute respiratory syndrome coronavirus 2-specific

- antibody responses in coronavirus disease 2019 patients., Emerging
  infectious diseases 26 (2020).
- [10] B. Sun, Y. Feng, X. Mo, P. Zheng, Q. Wang, P. Li, P. Peng, X. Liu,
  Z. Chen, H. Huang, et al., Kinetics of SARS-CoV-2 specific IgM and
  IgG responses in COVID-19 patients, Emerging Microbes & Infections
  (2020) 1–36.
- [11] Q.-X. Long, B.-Z. Liu, H.-J. Deng, G.-C. Wu, K. Deng, Y.-K. Chen,
  P. Liao, J.-F. Qiu, Y. Lin, X.-F. Cai, et al., Antibody responses to
  SARS-CoV-2 in patients with COVID-19, Nature medicine (2020) 1–4.
- [12] L. Shen, C. Wang, J. Zhao, X. Tang, Y. Shen, M. Lu, Z. Ding, C. Huang,
  J. Zhang, S. Li, et al., Delayed specific IgM antibody responses observed
  among COVID-19 patients with severe progression, Emerging Microbes
  & Infections 9 (2020) 1096–1101.
- [13] M. S. Suthar, M. G. Zimmerman, R. C. Kauffman, G. Mantus, S. L.
  Linderman, W. H. Hudson, A. Vanderheiden, L. Nyhoff, C. W. Davis,
  S. Adekunle, et al., Rapid generation of neutralizing antibody responses
  in COVID-19 patients, Cell Reports Medicine (2020).
- [14] R. Wölfel, V. M. Corman, W. Guggemos, M. Seilmaier, S. Zange, M. A.
  Müller, D. Niemeyer, T. C. Jones, P. Vollmar, C. Rothe, et al., Virological assessment of hospitalized patients with COVID-2019, Nature 581 (2020) 465–469.
- <sup>424</sup> [15] J. Lathrop, FDA, Analytical validation and points for discussion, 2016.
- <sup>425</sup> [16] S. Ubol, S. B. Halstead, How innate immune mechanisms contribute to

- antibody-enhanced viral infections, Clinical and Vaccine Immunology
  17 (2010) 1829–1835.
- [17] J. Xie, C. Ding, J. Li, Y. Wang, H. Guo, Z. Lu, J. Wang, C. Zheng,
  T. Jin, Y. Gao, et al., Characteristics of patients with coronavirus
  disease (COVID-19) confirmed using an IgM-IgG antibody test, Journal
  of medical virology (2020).
- [18] R Core Team, R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing, Vienna, Austria, 2019.
- [19] R. Scherer, PropCIs: Various Confidence Interval Methods for Proportions, 2018. R package version 0.3-0.
- [20] L. M. Kucirka, S. A. Lauer, O. Laeyendecker, D. Boon, J. Lessler, Variation in false-negative rate of reverse transcriptase polymerase chain
  reaction-based SARS-CoV-2 tests by time since exposure, Annals of
  Internal Medicine (2020).
- [21] A. T. Xiao, Y. X. Tong, S. Zhang, False-negative of RT-PCR and
  prolonged nucleic acid conversion in COVID-19: rather than recurrence,
  Journal of medical virology (2020).
- [22] H. Ma, W. Zeng, H. He, D. Zhao, D. Jiang, P. Zhou, L. Cheng, Y. Li,
  X. Ma, T. Jin, Serum IgA, IgM, and IgG responses in COVID-19,
  Cellular & Molecular Immunology (2020) 1–3.